Renal denervation (RDN)

Find all the latest content on renal denervation (RDN) published on this website.

Despite the existence of effective antihypertensive drugs, arterial hypertension remains a critical challenge for healthcare systems worldwide. Can catheter-based renal denervation (RDN) play an effective part in reducing, previously untreatable high blood pressure? Follow the latest research in this novel field along with the critical issues of blood pressure monitoring, imaging modalities, tools, devices and techniques as well as vascular access, bleeding risk and adjunctive pharmacotherapy…

Filtered By
Renal denervation

93 results

The 2023 ESH Hypertension Guidelines revisit the role of renal denervation

05 Sep 2023

The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...

Lucas Lauder

Author

Lucas Lauder

Author

Felix Mahfoud
The 2023 ESH Hypertension Guidelines revisit the role of renal denervation

Intervention around arterial hypertension

18 May 2023 – From EuroPCR 2023

Explore the realm of interventions in the context of arterial hypertension in this session: witness the remote haemodynamic monitoring of heritable pulmonary arterial hypertension, uncover the case of unilateral renal atrophy four years after renal sympathetic denervation, break the "boundaries" posed by calcification in renovascular hypertension,...

Intervention around arterial hypertension

EuroPCR 2023 Hotlines/Late-Breaking Trials: TAVI, hypertension, stroke prevention

17 May 2023 – From EuroPCR 2023

Want to find out what's happened lately in the field of hypertension and stroke prevention with TAVI? Check out this session where speakers give their take on what's essential to remember from a selection of studies: Primary outcome of the AnchorMan LAAO device randomised controlled trial...

Trials summaries on TAVI, hypertension and stroke prevention

Innovations in device-based treatment for hypertension

17 May 2023 – From EuroPCR 2023

Join this session to explore the latest innovations in device-based treatment for hypertension. Gain a comprehensive understanding of the evidence supporting the efficacy, durability, and safety of radiofrequency renal denervation, learn from renowned experts about the renal denervation procedure and receive valuable insights on patient selection...

Innovations in device-based

Patient selection for renal denervation in 2023

17 May 2023 – From EuroPCR 2023

While many clinical studies have demonstrated the superiority of renal denervation, the question that Felix Mahfoud asks Michel Azizi is when and in which patients to use this technique. Referring to the new consensus guidelines, our hypertension expert provides some answers in this exclusive interview recorded during EuroPCR 2023....

Patient selection for renal denervation in 2023

Update on renal denervation

16 May 2023 – From EuroPCR 2023

Check out these slides if you want to refresh your memory regarding this session presenting an update on renal denervation.

Renal denervation procedures

From proof to practice - Treating hypertension with ultrasound renal denervation

16 May 2023 – From EuroPCR 2023

Renal denervation: what are the latest clinical evidences and benefits? How to select the good candidate? How to establish a dedicated centre? All the anwers to these questions and more in this video.

From proof to practice

Renal denervation in the management of hypertension in adults: Consensus Document

15 Feb 2023

A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). The current position paper reviews the evidence for the safety and efficacy of renal denervation (RDN), summarizes aspects of the Expert Group’s discussion, and provides consensus statements...

Reviewer

Salvatore Brugaletta
Consensus renal denervation

Advances in left main bifurcation PCI and renal denervation

06 Oct 2022 – From AICT-ASIAPCR 2022

Discover more about treatment strategies and recent evidence for left main bifurcation, the latest Malaysian Working Group consensus statement on renal denervation, as well as reviewing patient-centred clinical judgement and individualised treatment plans.

Advances in left main bifurcation PCI and renal denervation

The RADIANCE II study: two months outcomes of a randomized trial of renal denervation versus a sham procedure for uncontrolled moderate hypertension

19 Sep 2022

Panos Xaplanteris reports on the outcomes of the RADIANCE II study, presented by Dr Ajay Kirtane at TCT 2022, that evaluated the outcomes of ultrasound-based renal denervation for patients with uncontrolled moderate hypertension.

Panagiotis Xaplanteris

Author

Panagiotis Xaplanteris
The RADIANCE II study: two months outcomes of a randomized trial of renal denervation versus a sham procedure for uncontrolled moderate hypertension